- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers.
- Abbott Laboratories,
- Beckman Coulter Inc.
- SQI Diagnostics.
- Quest Diagnostics.
- EUROIMMUN AG.
- AESKU Diagnostics GmbH & Co. KG.
- INOVA Diagnostics Inc.
- Crescendo Bioscience Inc.
- BioMerieux SA.
- Bio-Rad Laboratories Inc.
- Hemagen Diagnostics Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Autoimmune Disease Diagnosis Market:
In May 2022- The new Phadia 2500+ series of instruments by Thermofisher will be available for autoimmune testing in the United States. It offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.
The market is expanding due to reasons such as the increasing prevalence of autoimmune diseases, increased knowledge of disease diagnosis, and advancements in technology. Scleroderma, rheumatoid arthritis is among the conditions that are growing in frequency. One of the major elements contributing to the rise in the prevalence of autoimmune disorders is the combination between a person's genetic make-up, hormonal makeup, and sensitivity to specific infections. Scleroderma, for instance, affects 276 persons per million in the United States, according to research from the American Journal of Managed Care (AJMC) in May 2021. Therefore, the rise in autoimmune disease prevalence and public awareness is driving the demand for autoimmune disease diagnosis. Moreover, more product launches and increased growth tactics employed by key players will result in a market expansion. For instance, the most recent technological developments allow for the simultaneous measurement and identification of several antibodies. Numerous techniques, such as mass spectrometry and antigen microarray for antibody profiling, showed improved analytical sensitivity and repeatability. Using automated testing methods like automated indirect immunofluorescence, automated monoplex immunoassays, and automated multiplex immunoassays will also reduce the amount of time needed for diagnosis. Thus, the market is expected to rise over the forecast period. However, autoimmune diagnosis tests must go through several processes in order to reliably determine a positive outcome, so they take time to perform. For instance, it takes more than two days to receive the results of the rheumatoid factor (RF) test used to identify rheumatoid arthritis. The C-reactive protein (CRP) test, which determines the level of CRP in the blood, takes more than three days to get the results. The lengthy turnaround times associated with using traditional disease diagnosis techniques and the dearth of new testing technology are thus, some of the barriers inhibiting the industry's growth.